Overview

Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study)

Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the differences between albuminuria values determined as Urine Albumin-to-Creatinine Ratio (UACR)(log transformed) from baseline to last observation caused by paricalcitol between the group of control and group of treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Renal Iñigo Alvarez De Toledo
Collaborator:
Effice Servicios Para la Investigacion S.L.
Treatments:
Ergocalciferols